Shire Acquisition Provides Company with a Market-Ready Drug
Sally Mardikian PhD
Abstract
Shire adds yet another rare disease-targeting drug to its portfolio with its acquisition of Berlin-based Jerini.
Full Text: pdf html
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.